Krystal Applies for Phase 2 Clinical Trial Plan to Evaluate Camostat Efficacy in COVID-19 Patients

[Asia Economy Reporter Geum Bo-ryeong] Crystal announced on the 26th that it has applied to the Ministry of Food and Drug Safety for an IND (Investigational New Drug) plan for a Phase 2 clinical trial to evaluate the efficacy and safety of Camostat in COVID-19 patients confirmed to be infected with the SARS-CoV-2 virus.

The clinical trial will involve 100 patients aged 18 or older with mild to moderate COVID-19, confirmed positive for SARS-CoV-2 infection by RT-PCR (Real-Time Reverse Transcription Polymerase Chain Reaction), who have exhibited at least one symptom or sign of COVID-19 within 48 hours. The trial period will be a total of 28 days, including 7 days of administration and observation.